Cholecystokinin receptor blockers have been reported to have variable effects in the treatment of anxiety disorders.
In recent years, some non-peptide small molecular N-type Ca2+ channel blockers have been reported.
Third, we are uncertain whether the use of nimodipine in our patients might have contributed to the changes in HRV during follow-up since calcium channel blockers had been reported to affect HRV [41, 42].
84 Beta blockers have been reported to exacerbate psoriasis.
In addition, numerous reports and case series of neurological adverse events due to anti-TNFα blockers have been reported.
Renin-angiotensin system (RAS) blockers have been reported to reduce VFA and decrease vascular inflammation [ 19, 20].
Finally, calcium channel blockers have been reported to facilitate successful weaning in the particular context of hypertrophic cardiomyopathy [ 23].
Other non-hemodynamic effects of beta-blockers can be considered: beta-1-selective adrenergic receptor blockers have been reported to increase endothelial NO production, which may facilitate microcirculation recruitment [ 37].
3 Finally, various investigational small-molecule blockers have been reported for the protein interaction between VLA4 VCAM, 4 B7.1–CD28, 5 oestrogen-related receptor-α and its co-activator, 6 and protein kinase C-iota and its effector PAR6.
Positive effects for D2 dopamine receptor blockers have been reported in the treatment of tics since 40 years (in average a marked decrease of tics in about 70% of cases [ 237]).
Up to now, several drugs, including statins and angiotensin II receptor blockers, have been reported to offer protection against oxidative stress in diabetic patients with vascular complications [ 2, 4, 6, 7].
